Sources
- cryptonews.com /
- tokenpost.com /
- altcoinbuzz.io /
- coinpedia.org /
- coinpedia.org /
- crypto-economy.com /
- theblock.co /
- tokenpost.com /
- coinpaper.com /
- tokenpost.com /
- coinmarketcap.com /
- news.bitcoin.com /
- tokenpost.com /
- altcoinbuzz.io /
- coinspress.com /
- cryip.co /
Tickers
Canary Capital’s Staked INJ ETF (ticker INJC) has begun trading on Nasdaq, giving investors exposure to Injective’s INJ token plus potential staking rewards through a standard brokerage account, with the fund planning to stake at least 90% of its Injective holdings under normal conditions, using BitGo as custodian and charging a 1.10% sponsor fee. On November 4, 2026, Canary Capital filed a prospectus with the SEC for a new staked Injective ETF that holds tokens directly rather than through derivatives or a trust structure, and keeps 70% of staking rewards for investors. Injective rose about 5% on its ETF debut day even as Bitcoin f…
Canary Capital Group LLC filed a prospectus with the SEC on November 4, 2026 for a new exchange-traded fund designed to give investors exposure to Injective, a blockchain network focused on decentralized finance applications, while also capturing staking rewards typically unavailable through a standard spot ETF structure.
Fund Structure
The fund, trading under the ticker INJC on Nasdaq, will hold Injective tokens directly rather than tracking the asset through derivatives or a trust structure that avoids direct custody.
According to the filing, the fund keeps 70% of the staking rewards for investors.
Market Context
Injective rose about 5% on its ETF debut day, even as Bitcoin fell.